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Summary
Slit is a secreted protein known to function through the Roundabout (Robo) receptor as a chemorepellent in axon guidance
and neuronal migration, and as an inhibitor in leukocyte chemotaxis. Here we show Slit2 expression in a large number of
solid tumors and Robo1 expression in vascular endothelial cells. Recombinant Slit2 protein attracted endothelial cells and
promoted tube formation in a Robo1- and phosphatidylinositol kinase-dependent manner. Neutralization of Robo1 reduced
the microvessel density and the tumor mass of human malignant melanoma A375 cells in vivo. These findings demonstrate
the angiogenic function of Slit-Robo signaling, reveal a mechanism in mediating the crosstalk between cancer cells and
endothelial cells, and indicate the effectiveness of blocking this signaling pathway in treating cancers.
Introduction Several families of extracellular proteins including the ne-
trins, the semaphorins, the ephrins, and the Slits function as
Angiogenesis is a cellular process of capillary sprouting and guidance cues to attract or repel projecting axons and migrating
configuring of neovasculature. It is of crucial importance in a neurons during the development of the nervous system (Tessier-
variety of physiological and pathological conditions, including Lavigne and Goodman, 1996; Dickson, 2002). Slit is a new family
ischemia and hypoxia, wound healing, diabetic retinopathy, of secreted repellents in axon guidance (Wang et al., 1999;
macular degeneration, neovascular glaucoma, psoriasis, rheu- Brose et al., 1999; Kidd et al., 1999; Li et al., 1999) and neuronal
matoid arthritis, and cancer growth and metastasis (Hanahan migration (Wu et al., 1999). The receptor for Slit is the transmem-
and Folkman, 1996; Risau, 1997; Holash et al., 1999; Carmeliet brane protein Roundabout (Robo) (Kidd et al., 1998, 1999; Brose
and Jain, 2000). The obligatory requirement of angiogenesis for et al., 1999; Li et al., 1999). Slit has recently been shown to be
the growth and metastasis of cancers is now well recognized. an endogenously available inhibitor of leukocyte chemotaxis
For instance, the growth of solid tumors requires concomitant (Wu et al., 2001). There are three Slits and four Robos in mam-
expansion of vascular networks to maintain the blood supply of
mals (for a recent review, see Wong et al., 2002). Some of theoxygen and nutrients; an insufficient supply of blood (to tissues
Slits and Robos are expressed in adult tissues and outsidelocated more than 100 to 200 m away from blood vessels)
the nervous system (Holmes et al., 1998; Wu et al., 2001). Forcan lead to cancer necrosis. Although vascular endothelial cell
example, SLIT2 mRNA in endothelial cells and ROBO1 mRNAgrowth factors (VEGFs), fibroblast growth factors (FGFs), and
in leukocytes have been reported (Wu et al., 2001). However,several other angiogenic molecules are indispensable for vessel
it has not been determined whether human cancer cells canformation (Gale and Yancopoulos, 1999; Yancopoulos et al.,
express these genes, either at the mRNA or protein levels. Po-2000; Folkman, 2001, 2002; Kerbel and Folkman, 2002), the
tential roles of Slit-Robo signaling in pathological conditionsmolecular and cellular mechanisms regulating tumor angiogen-
esis are still not well understood. have been suggested (Wu et al., 2001), but not established. We
S I G N I F I C A N C E
Communication between tumor cells and vascular endothelial cells is known to be important in tumor-induced angiogenesis.
Mechanistic understanding of tumor-induced angiogenesis is crucial for designing therapeutic approaches. Our results have revealed
a previously unsuspected role of Slit-Robo signaling in tumor angiogenesis and shown the importance of this pathway in tumor
growth. Interestingly, Slit attracts vascular endothelial cells, which is opposite to its roles as repellents and inhibitors in axon guidance
and neuronal and leukocyte migration. These basic findings allowed us to design a strategy of neutralizing Robo1 activity for inhibition
of tumor growth. Our results have uncovered a molecular mechanism for tumor-induced angiogenesis and led to the finding of a
novel molecular target for controlling tumor growth.
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have now investigated whether Slit and Robo could play roles
in tumor angiogenesis in vitro and in vivo. Results from our
current studies have established that Slit-Robo signaling at-
tracts vascular endothelial cells, which significantly extends the
previous conclusion of a fundamentally conserved mechanism
for guiding somatic cell migration (Wu et al., 2001; Rao et al.,
2002). Furthermore, our findings of Slit-Robo signaling in pro-
moting tumor-induced angiogenesis indicate that Slit and Robo
play significant roles in pathological conditions. The effective-
ness of Robo blockade in limiting tumor growth demonstrates
a novel target as well as molecular tools for cancer therapy.
Results
Expression of Slit2 on cancer cells and Robo1
in endothelial cells
Using reverse-transcription coupled to the polymerase chain
reaction (RT-PCR), we found that A375 cells, a cell line derived
from a human malignant melanoma, expressed SLIT2 mRNA
and human umbilical vein endothelial cells (HUVECs) expressed
ROBO1 mRNA, respectively (Figures 1A and 1D). The expres-
sion of SLIT2 mRNA in A375 cells and ROBO1 mRNA in HUVECs
was confirmed by Northern blotting with 32P-labeled SLIT2 and
ROBO1 cDNA fragments (Figures 1B and 1E). The G3PDH
mRNA, a house-keeping gene, was probed as the loading con-
trol of total input RNA. We generated antibodies to Slit2 and
Robo1 and detected the expression of Slit2 protein in A375
cells (Figure 1C) and Robo1 protein in HUVECs (Figure 1F).
Slit2/293 cells and Robo1/293 cells were used as the positive
controls, and V/293 cells were used as the negative controls
(Li et al., 1999; Wu et al., 1999; Wu et al., 2001). The expression
of Slit2 in A375 cell derived solid tumors was detected by immu-
nohistochemical staining with the anti-Slit2 antibody, but not
with the preimmune IgG (Figure 1G). The expression of Robo1,
which co-localized with vWF (von Willbrand factor) expression,
in tumor endothelial cells was visualized with the anti-Robo1 Figure 1. Expression of Slit2 in A375 cells and Robo1 in endothelial cells
antibody (Figure 1H), but not with the preimmune IgG (data not
A and D: SLIT2 mRNA in A375 cells and ROBO1 mRNA in HUVECs were
shown). Interestingly, there appeared to be a gradient of Slit2 determined by RT-PCR. Arrows indicated the positive SLIT2 band (1.0 kb)
protein with a higher concentration near the center of the tumor and ROBO1 band (500 bp), respectively. Human -ACTIN mRNA (1.0 kb)
was also assayed as a control for RT-PCR. P-C (PCR control) lane was PCR inand a lower concentration in the periphery (Figure 1G). The
the absence of the templates; RT-C (RT control) was PCR using the templateexpression of Slit2 in malignant melanoma and Robo1 in tumor
generated without the reverse transcriptase.endothelial cells suggests a possible paracrine Slit2/Robo1 in- B and E: Northern blotting of SLIT2 (5.0 kb) in A375 cells and ROBO1 (4.6
teraction in the pathogenesis of malignant melanoma. kb) in HUVECs. G3PDH (a house-keeping gene; 1.4 kb) was used as a
loading control.
C and F: Protein expression of Slit2 in A375 cells (200 kDa) and Robo1Cell surface localization of Slit2 and its upregulation
(200 kDa) in HUVECs was detected by anti-Slit2, anti-Robo1, and 9E10Although Slit2 is predicted to be a soluble protein, it has been
Abs, but not by preimmune IgG. Slit2/293 cells and Robo1/293 cells were
shown to bind to Glypican-1 and to be localized on the cell used as the positive control while V/293 cells were used as the negative
surface in the brain, in a heparan sulfate proteoglycan (HSPG)- control. 9E10 was a monoclonal antibody against the c-myc tag of Slit2
fusion protein.dependent manner (Liang et al., 1999; Hu, 2001; Ronca et al.,
G and H: Immunohistochemical staining of tumors with the anti-Slit2 Ab2001). Similarly, we found that the majority of Slit2 was associ-
(an arrow indicated the expression of Slit2 on A375 cells; serial paraffin-ated with A375 cells in cell culture conditions, even though a embedding sections), with the anti-Robo1 Ab (an arrow indicated the ex-
small amount of Slit2 was also detected in the supernatants pression of Robo1 on endothelial cells within the tumors; serial cryostat
sections) or with preimmune IgG. The expression of Robo1 was colocalized(Figure 1I). Pretreatment of A375 cells with heparin increased
with the vWF staining using an anti-vWF Ab. Scale bar, 100 m for G, 20 mthe amount of Slit2 in the supernatants and, at the same time,
for the inserts in G, and 50 m for H.decreased the amount of Slit2 in the whole cell lysates, support-
I: Slit2 in the supernatants and the lysates of A375 cells without or with
ing the HSPG dependence for cell surface localization of Slit2 heparin and/or TNF-.
on A375 cells. J: Affinity-purified Slit2 was silver stained or immunoblotted with 9E10.
To explore the molecular mechanism governing the forma-
tion of the Slit2 gradient, we examined whether cytokines could
regulate Slit2 expression in A375 cells. TNF- (tumor necrosis
factor-) increased the expression of Slit2 (Figure 1I). Similar
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findings were also observed using IL-1 (interleukine-1; data 2D–2F). RoboN added in the bath neutralized the Slit2-induced
directional migration, but had no inhibitory effect on the bFGF-not shown), indicating that the upregulation of Slit2 in response
to the secretion of proinflammatory mediators (and perhaps due induced migration (Figures 2E and 2F). These data indicate that
Slit2 can attract the directional migration of vascular endothelialto hypoxia or expression of oncogenes) could be involved in
increasing Slit2 in the center of A375 cell-derived solid tumors, cells through Robo1.
thus resulting in the generation of a gradient.
Angiogenic activity of Slit2 and role of Slit2-Robo1
signaling in tumor-induced angiogenesisAttraction of endothelial cells by Slit2
We used several approaches to investigate whether and how To investigate the potential regulation of angiogenesis by Slit2,
we first examined whether Slit2 could induce the differentiation,Slit could regulate the migration of endothelial cells. We first
tested whether Slit2 had any chemotactic effects on the migra- specifically tube formation of HUVECs in vitro. Slit2 increased
the generation of tubular networks in a dose-dependent mannertion of HUVECs using Boyden chamber assay. Similar to bFGF
(basic fibroblast growth factor), purified recombinant human (Figures 2G and 2H). Preincubation of Slit2 with RoboN (Figures
2G and 2H), or preincubation of HUVECs with R5 (Figure 2I),Slit2 protein (Figure 1J) induced the migration of HUVECs in a
dose-dependent manner (Figure 2A). Preincubation of Slit2 with neutralized the effect of Slit2, resulting in fewer and shorter tube
structures. These results indicate that Slit2 has an angiogenicRoboN (an extracellular fragment of Robo1 that is a known
inhibitor for the Slit2/Robo1 interaction; Wu et al., 1999, 2001) activity in vitro. It should be mentioned that Slit2 had no detect-
able activity on the proliferation of HUVECs (data not shown).or preincubation of HUVECs with R5 (an IgG2b monoclonal anti-
body to the first immunoglobulin domain of Robo1), but not Because A375 cells expressed Slit2 and Slit2 induced the
migration and the tube formation of endothelial cells in vitro,with an IgG2b control, significantly neutralized the Slit2-induced
migration (Figures 2A and 2B). In contrast, RoboN or R5 did not we tested the pathological significance of Slit2-Robo1 signaling
in tumor angiogenesis using the xenografted animal model. Foraffect the bFGF-induced migration of HUVECs. These results
indicate that Slit2 can promote the migration of HUVECs through this purpose, we transfected A375 cells with the RoboN plasmid
or the plain vector followed by antibiotic selection and singleRobo1.
To determine the functional significance of Robo1, we per- cell cloning. Using this approach, three stable single cell clones
expressing RoboN (designated as RoboN/A375_C1, C2, andformed reconstitution experiments using Robo1/293 cells. Slit2
and bFGF both promoted the migration of Robo1/293 cells, but C3 cells) and one stable cell clone expressing the vector (desig-
nated as V/A375 cells) were generated. These clones were char-RoboN only neutralized Slit2-induced, but not bFGF-induced,
migration of Robo1/293 cells (Figure 2C). Furthermore, bFGF, acterized by immunoblotting for RoboN, Slit2, and VEGF
(-tubulin as loading control) expression to ensure that the simi-but not Slit2, triggered the migration of V/293 cells, indicating
that HEK293 cells express endogenous receptors for bFGF. lar amounts of RoboN were expressed in all three C1, C2, and
C3 clones and that no alterations of Slit2 and VEGF expressionEvidently, Robo1 is essential for the cell migration mediated by
Slit2, but not mediated by bFGF, suggesting a specific role for were detected among RoboN/A375_C1, C2, C3, and V/A375
clones (Figure 3A). In addition, they were tested for in vitroRobo1 in mediating cellular responses to Slit2.
To determine whether Slit2 guided the direction of endothe- growth rates to ensure that they all grew at similar rates in cell
culture conditions (Figure 3B).lial cell migration, rather than simply increasing the motility (non-
directional or random migration) of endothelial cells, we adopted These transfectants were then inoculated subcutaneously
into athymic nude mice. When compared to those from V/A375a technique that had been successfully used for direct observa-
tion of axon projection (Song et al., 1997; Ming et al., 2002). cells, tumors resulting from RoboN/A375_C1, C2, and C3 cells
had significantly reduced microvessel densities (Figures 3C andThis device could generate a microscopic gradient of a specific
protein delivered in a picoliter volume through a micropipette 3D). Furthermore, the tumor volumes and masses from Robo1/
A375_C1, C2, and C3 cells were all markedly smaller than thoseby repetitive pressue (Ho¨pker et al., 1999). We loaded a micro-
pipette with Slit2 or bFGF protein and placed its tip at a distance from the control V/A375 (Figures 3E and 3F).
As an alternative approach to the RoboN construct, weof 100 m away from the center of individual HUVECs. The
entire trajectory of the migrating HUVECs was recorded in a tested R5, the function-blocking monoclonal antibody against
the first immunoglobulin motif of Robo1. RoboN would blocktimelapse microscopy. As shown in the examples (Figure 2D),
the endothelial cell did not migrate when PBS (phosphate buf- Slit signaling by absorbing Slit proteins, whereas R5 should
block Robo specifically, thereby providing a complementaryfered saline, pH 7.4) was applied. However, it migrated toward
the micropipette loaded with Slit2 in a time-dependent manner, approach to inhibit Slit2-Robo1 signaling. We found that, com-
pared to an IgG2b control, R5 clearly reduced tumor microvesselindicating that Slit2 was a chemoattractant for HUVECs. In con-
trast, HUVECs could migrate toward or away from the micro- densities and tumor masses (Figures 3H–3M).
To substantiate the above conclusion, we further examinedpipette loaded with bFGF in a time-dependent manner (an ex-
ample of a cell migrating away from bFGF was shown in Figure the effects of Slit2 overexpression in tumor angiogenesis and
growth. We proposed that Slit2 overexpression could induce2D). The entire sets of experimental data could be presented
as the cumulative distribution (%) versus migrated distance (m; the exaggerated tumor angiogenesis and the accelerated
expansion of tumor mass. After transfection of A375 cells withFigure 2E) and, alternatively, as the migrated distance (m)
versus the various treatment (Figure 2F). Cell migration toward a the Slit2 plasmid or the plain vector as described above, we
generated two stable single cell clones expressing Slit2 (desig-Slit2 gradient established an attractive role for the Slit2-induced
endothelial cell migration (Figures 2D–2F). In contrast, bFGF nated as Slit2/A375_C1 and C2 cells) and one stable cell clone
expressing the vector (designated as V/A375 cells). They wereincreased the motility of HUVECs by inducing the migration of
HUVECs; however, this migration was not directional (Figures characterized by immunoblotting for Slit2 and VEGF (-tubulin
CANCER CELL : JULY 2003 21
A R T I C L E
Figure 2. Slit2-induced migration and tube formation of endothelial cells
Migrations of HUVECs (A and B), Robo1/293 cells, and V/293 cells (C) were measured using Boyden chamber assay. Results were calculated as mean 
SD values from triplicate measurements of three to six separate experiments.
D: For measurement of directional migration of HUVECs, a protein gradient was applied from a micropipette by the pulsatile application of 0.15 M Slit2
or 1 M bFGF. Phase-contrast micrographs of endothelial cells were recorded in a timelapse mode after exposure to the Slit2 or bFGF gradients (min). The
arrowhead indicated the direction in which the protein was loaded through the micropipette. Scale bar, 8 m.
The migratory directions induced by Slit2 and bFGF (E) and migrated distances (F) were determined (each dot representing the migratory direction and
distance of a single endothelial cell). *, p  0.05 and **, p  0.01, Kolmogorov-Smirnov test.
G: Tube formation of HUVECs on Matrigel was visualized by phase-contrast microscopy. Scale bar, 60 m.
H and I: The effects of Slit2 and bFGF on the tube formation of HUVECs without or with RoboN or R5. Results were calculated as mean  SD values from
triplicate measurements of three separate experiments.
as loading control) expression to ensure that the similar amounts Furthermore, the tumor volumes and masses from Slit2/A375_C1
and C2 cells were all significantly bigger than those from theof Slit2 were overexpressed in both C1 and C2 clones and that
no alterations of VEGF expression were detected among C1, control V/A375 (Supplemental Figures S1E and S1F). These in
vivo results demonstrate the biological significance of Slit2-C2, and V/A375 clones (Supplemental Figure S1A at http://
www.cancercell.org/cgi/content/full/4/1/19/DC1). In addition, Robo1 signaling in tumor angiogenesis and growth.
As endothelial cells expressed both Slit2 and Robo1 andthey were tested to ensure that they all grew at similar rates in
cell culture conditions (Supplemental Figure S1B). Slit2 reportedly inhibited leukocyte chemotaxis (Wu et al., 2001),
we measured the leukocyte counts in the blood and in theAfter inoculation of these transfectants, tumors resulting
from Slit2/A375_C1 and C2 cells had significantly increased solid tumors of these xenografted mice. We found no clear
differences among these groups (Figures 3G and 3N and Sup-microvessel densities if compared to those from V/A375 cells
(Supplemental Figures S1C and S1D on Cancer Cell website). plemental Figure S1G). The equivalent numbers of leukocytes
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Figure 3. Inhibition of angiogenesis and growth of malignant melanoma
A: Detection of RoboN by the anti-Robo1 Ab in three single cell stable clones of RoboN/A375_C1, C2, and C3, but not in one single cell stable clone of
V/A375. Slit2, VEGF, and -tubulin were also detected by the respective Abs to Slit2, VEGF, and -tubulin in all these cell clones. No signal was evident with
preimmune rabbit IgG (data not shown).
H: R5, but not an IgG2b control, recognized Robo1. The anti-HA (hemagglutinin) Ab (Clontech), which recognized the HA tag of Robo1 fusion protein in
Robo1/293 cells, was used as the positive control.
B and I: Measurement of growth rates for V/A375 cells and RoboN/A375_C1, C2, and C3 cells (B) and for A375 cells in the presence of mouse IgG2b or R5
(I). Results were expressed as the mean  SD values from triplicate measurements of three separate experiments.
C and J: Immunohistochemical staining of blood vessels within tumors of V/A375 cells and RoboN/A375_C2 cells (C) and of A375 cells treated with mouse
IgG2b and R5 (J) using an anti-CD31 Ab. No positive staining was detected when preimmune IgG was used (data not shown). Scale bar, 20 m.
D and K: The mean  SD values of microvessel densities (CD31 staining) were statistically analyzed using the ImageTool software for tumors of V/A375 cells,
RoboN/A375_C1, C2, and C3 cells (D) and of A375 cells treated with an IgG2b control or R5 (K; n  14 for each group).
E and L: The mean  SD values of tumor volumes for tumors from V/A375 cells, RoboN/A375_C1, C2, and C3 cells (E) and from A375 cells treated with
mouse IgG2b or R5 (L; n  14 for each group).
F and M: The mean  SD values of tumor weights for tumors from V/A375 cells, RoboN/A375_C1, C2, and C3 cells (F) and from A375 cells treated with
mouse IgG2b or R5 (M; n  14 for each group).
G and N: Leukocyte counts in blood and in tumors derived from V/A375 cells, RoboN/A375_C1, C2, and C3 cells (G) and from A375 cells treated with
mouse IgG2b or R5 (N; n  14 for each group). *, p  0.05 and **, p  0.01, Student’s t test.
within the tumors were further confirmed by hematoxylin and nating from various tissues and organs. Slit2 was expressed
in A375 cells (malignant melanoma), SCaBER cells (bladdereosin (H&E) staining of the tissue sections (data not shown).
Slit2 therefore does not appear to be involved in leukocyte squamous carcinoma), SK-N-SH cells (neuroblastoma), NCI-
trafficking into malignant melanoma in vivo. H446 cells (small cell lung cancer), T24 cells (transitional cell
carcinoma of urinary bladder), LoVo cells (colon adenocarci-
noma), ZR-75-30 cells (breast cancer), CNE cells (nasopharyn-Expression of Slit2 in human cancers
To explore the general significance of our findings, we examined geal carcinoma), SMMC-7721 cells (hepatocellular carcinoma),
Acc-2 and Acc-M cells (both were adenoid cystic carcinoma ofthe expression of Slit2 in multiple human cancer cell lines origi-
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Figure 4. Expression of Slit2 in cancers
A: Immunoblotting of cell lysates from various
cancer cell lines using the anti-Slit2 Ab and the
anti--tubulin Ab. The Slit2/293 cells were used as
the positive control.
B: Northern blotting of SLIT2 and G3PDH mRNAs
using 32P-labeled SLIT2 and G3PDH cDNA frag-
ments. C: Immunohistochemical staining of vari-
ous human cancers with the anti-Slit2 Ab. Arrows
indicated the expression of Slit2 on tumor cells.
Scale bar, 10 m.
salivary gland), and A673 cells (rhabdomyosarcoma; Figure 4A). screened a variety of chemicals for their effects on the migration
and the tube formation of HUVECs induced by Slit2. We foundHowever, Slit2 was not detected in A549 cells (lung cancer),
that Wortmannin and LY294002 (both PI-3K inhibitors; TokerHeLa cells (cervical epithelial adenocarcinoma), MCF-7 cells
and Cantley, 1997; Fruman et al., 1998), but not KT5823 (an(breast adenocarcinoma), and 786-O cells (primary renal cell
inhibitor of protein kinase G), attenuated Slit2-induced migra-adenocarcinoma). The expression of Slit2 in these cancer cell
tion, but not bFGF-induced migration, of HUVECs in a dose-lines was confirmed by Northern blotting with 32P-labeled SLIT2
dependent manner (Figures 6A and 6B). Both inhibitors alsocDNA fragment (Figure 4B). Again, the -tubulin immunoblotting
attenuated directional migration (Figure 6E) and tubulogenesisand the G3PDH Northern blotting were used as the loading
induced by Slit2 (Figures 6C and 6D). Biochemically, Slit2, butcontrols of input proteins and RNAs (Figures 4A and 4B).
not bFGF, could activate PI-3K in HUVECs, resulting in theThe finding of Slit2 expression in a variety of cancer cell
increased radioactivity of 32P-ATP-labeled inositol phospholip-lines is consistent with the recent report of Slit2 expression in
ids (Figures 6F and 6G). These data demonstrate that activationprostate cancers using a RT-PCR-based approach (Latil et al.,
of PI-3K in HUVECs by Slit2 is required for directional migration2003). Along this line of investigation, we examined human sam-
and tube formation of vascular endothelial cells.ples of malignant melanoma, rectal mucinous adenocarcinoma,
invasive breast carcinoma, gastric squamous carcinoma, and
hepatocellular carcinoma for Slit2 expression (Figure 4C). We
found that in all these cancer samples, Slit2 was expressed in the
cancerous tissues, but not in the nearby regions of apparently
normal tissues. The positive staining of Slit2 was found in 3
malignant melanomas (n  7), 51 breast carcinomas (n  72;
70.8% positive), 42 colorectal carcinomas (n 65; 64.6% posi-
tive), and 38 gastric carcinomas (n  74; 51.4% positive). Nota-
bly, Slit2 staining appeared to be more intense in the areas of the
tumor, where more cancer cells and blood vessels (visualized by
an antibody to vWF) existed within human colon carcinoma
(Figure 5A). In contrast, less Slit2 staining was detected where
there were fewer cancer cells and vasculatures. A similar corre-
lation was also found in human breast carcinoma (data not
shown). Furthermore, Slit2 was absent in normal and hyperplas-
tic colon tissues, began to appear in colon adenomas (3/14;
21.4% positive), and upregulated in colon carcinoma (42/65;
64.6% positive; Figure 5B). These data suggest a correlation
Figure 5. The correlation of Slit2 expression with MVD alterations and Slit2
among cancerous alterations, Slit2 expression, and the mi- expression in carcinoma stage
crovessel density within tumors.
A: Immunohistochemical staining of human colon carcinoma with the anti-
Slit2 and anti-vWF Abs. Arrows indicated the Slit2 expression on cancer cells
and arrowheads indicated the microvessels within the solid tumors. ScaleInvolvement of phosphatidylinositol-3 kinase (PI-3K)
bar, 100 m for the upper panel and 50 m for the lower panel.in Slit2-induced migration and tubulogenesis
B: Immunohistochemical examination of the tissue sections from humanof endothelial cells
colon adenoma (weak staining) and carcinoma (strong staining) using the
In an effort to explore downstream molecular mechanisms of anti-Slit2 Ab. No Slit2 staining for the normal or hyperplastic colon tissues.
Scale bar, 50 m.the Slit2-Robo1 signaling in vascular endothelial cells, we
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Figure 6. Requirement of PI-3K for Slit2-induced
migration and tube formation of HUVECs
A and B: The migrations of HUVECs, without or
with Wortmannin, LY294002, or KT5823, were
measured when Slit2 (A) or bFGF (B) was present
in the lower chambers using Boyden chamber
assay. Results were calculated as mean  SD
values from triplicate measurements of three
separate experiments.
C and D: The tube formations of HUVEC, in the
absence or presence of inhibitors, were exam-
ined when Slit2 (C) or bFGF (D) was present.
Results were calculated as mean  SD values
from triplicate measurements of three separate
experiments.
E: The migrated distances of HUVECs without or
with inhibitors were analyzed (each dot repre-
senting the migratory direction and distance of a
single endothelial cell). *, p  0.05, Kolmogorov-
Smirnov test.
F: Following treatment of HUVECs with Slit2 or
bFGF, PI-3K was precipitated and used to cata-
lyze PI to 32P-ATP-labeled phosphatidylinositol
phosphalipids (PIP). The reactants were sepa-
rated and visualized.
G: The means  SD values of the radioactivity
for the P32-labeled PIP from three independent
experiments. *, p  0.05, Student’s t test.
Discussion mor-induced angiogenesis. Because we can inhibit tumor
growth in vivo by specific neutralization of the Slit2-Robo1 inter-
Our results have concluded that in addition to its well-character- action with either the extracellular part of Robo1 or R5, the
ized functions in axon guidance and neuronal migration, Slit2 function-blocking monoclonal antibody for Robo1, it not only
can attract vascular endothelial cells and promote tumor-induced indicates the importance of Slit-Robo signaling in tumor-induced
angiogenesis and tumor growth, but also provides novel molec-angiogenesis. This strengthens the idea of fundamental conser-
vation of guidance mechanisms for all somatic cells (Wu et ular tools for attenuating tumors. Taken together, our results
have significant implications in both basic mechanisms andal., 2001; Rao et al., 2002). Our results also indicate that Slit2
expressed in solid tumors can communicate with Robo1 ex- clinical applications.
Migratory behavior is distinct among different cell types,pressed in endothelial cells, revealing a pathway mediating tu-
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with different speeds and different morphologies. Previously, Slits (Wong et al., 2002), which have not been tested in tumors.
It is possible that Slit1 and Slit3 could also be expressed indistinct guidance cues have been found for different cells, with
chemotactic factors functioning through seven transmembrane some tumors. Similarly, we have so far focused on Robo1,
whereas there are three other Robos. Considering the possibilityG protein-coupled receptors (GPCRs) discovered to be impor-
tant for nonneuronal cells and guidance cues functioning through that different Robos could be involved in angiogenesis, we sus-
pect that RoboN (made from the extracellular part of Robo1)single transmembrane receptors shown to be important for neu-
rons. Only recently have neuronal guidance cues been found to may block all three Slits and that the R5 antibody (made by
immunization of and screening against the first immunoglobulindirectly guide the migration of leukocytes (Wu et al., 2001) while
leukocyte chemotactic factors were shown to function directly domain of Robo1) may block other Robos as well as Robo1.
The result of immunohistochemical staining suggests thaton neurons (Lu et al., 2001, 2002; Klein et al., 2001; Zhu et al.,
2002; Xiang et al., 2002). Those findings based on neurons Slit2 protein is expressed in a center-to-periphery gradient in
and leukocytes led to the proposal of the idea of conserved solid tumors. It will be interesting to investigate whether this
molecular mechanisms among all somatic cell types (Wu et al., gradient contributes to the exaggerated angiogenesis in the
2001; Rao et al., 2002). Results reported in the present study center of solid tumors and what is the mechanism for forming
significantly strengthen the idea by extending the conservation and maintaining the Slit2 gradient. It has been reported that
to vascular endothelial cells and to pathological processes. Slit2 associates with HSPGs on Glypican-1 expressed on the
All previous studies of Slits in neurons and leukocytes indi- neuronal cells in the central nervous system. Likewise, the gradi-
cate that Slits are repulsive or inhibitory for migrating cells (re- ent formation of Hedgehog requires Tout-velu, an enzyme in-
cently reviewed in Wong et al., 2002). It is thus curious that Slit2 volved in HSPG biosynthesis (Bellaiche and Perrimon, 1998).
has been found to function as a chemoattractant for vascular Further, overexpression of the glypican HSPG, called Dally-like,
endothelial cells. Previous studies by Poo and colleagues have leads to higher than normal levels of extracellular Wingless (Wg)
shown that the same guidance cue can either attract or repel accumulation (Tsuda et al., 1999). In contrast, clones defective
the same axons depending on intracellular cAMP and cGMP in HSPG biosyhthesis bind to lower than normal levels of extra-
levels (Song et al., 1997). It will be interesting to test whether cellular Wg and are deficient in Wg signaling (Baeg et al., 2001).
cAMP and cGMP play a role in endothelial cell migration and Notum, a member of the /-hydrolase superfamily, influences
angiogenesis, in addition to their roles in endothelial responses the distribution of Wg by modifying HSPG Dally-like and Dally
to Slit2. (Gira´dex et al., 2002). Our finding that pretreatment of A375
We have found that PI-3K is involved in endothelial cell cells with heparin increases the amount of Slit2 in the superna-
responses to Slit2. It will be interesting to compare the pathways tants and, at the same time, decreases the amount of Slit2 in
mediating attractive responses in endothelial cells to those in the whole cell lysates also supports the association of Slit2 with
neurons, although the intracellular transduction pathway for Slit- HSPGs on cancer cells. It remains to be determined whether
Robo signaling in neuronal repulsion is only beginning to emerge Slit2 is associated with Glypican-1 HSPGs expressed on cancer
(Bashaw et al., 2000; Fritz and VanBerkum, 2000; Wong et al., cells, whether regulation of Glypican-1 HSPGs alters the tempo-
2001). For example, it would be interesting to know whether ral and spatial distribution of Slit2 on cancer solids, and whether
PI-3K inhibitors, such as Wortmannin and LY294002, could Tout-velu and/or Notum could affect the surface localization of
prevent the repellant action of Slit2 on axon guidance and neu- Slit2 by modulating Glypican-1 HSPGs.
ronal migration, and the inhibitory action of Slit2 on leukocyte The results presented here have demonstrated the role of
chemotaxis. Slit2-Robo1 signaling in tumor angiogenesis and have evaluated
Extensive studies of genetically engineered mouse models the significance of this signaling pathway in the pathogenesis
of spontaneous tumorigenesis and pathological examinations of cancers. However, whether this discovery can be translated
of human cancers have delineated discrete stages of carcino- to the diagnosis, treatment, and prevention of malignant tumors
genesis, including pre-angiogenic hyperplasia/dysplasia/carci- remains to be determined. For example, can the immunohisto-
noma in situ (CIS), angiogenic dysplasia/CIS, and small tumor chemical staining of Slit2 be used as a reliable marker for the
and large tumor/invasive carcinoma (Hanahan and Folkman, diagnosis of certain cancers? Are the measurements of Slit2 in
1996). Among these stages, angiogenesis is switched on during the blood and the urine useful for screening certain carcinomas?
the premalignant stage of tumor development, persisting there- Considering that the neutralization of Robo1 activity incom-
after. Although VEGF-mediated signaling is generally believed pletely reduces the microvessel density and the tumor mass of
to be essential for the angiogenic switch, the expression of VEGF malignant melanoma (Figure 3), it will be interesting to test the
and its cognate receptors, flt-1 (VEGF-R1) and flk-1 (VEGF-R2), efficacy of a combined therapy using inhibitors for both VEGF
appears to be constitutive; no alterations in the expression of and Slit2 for treatment of cancers. It is also interesting to test
these molecules can be clearly detected (Bergers et al., 1999, whether Slit2 has any synergistic effects on the angiogenic activ-
2000; Inoue et al., 2002). The disappointing results from the ities of VEGF, FGF, ephrin, and other known angiogenic factors.
clinical trial using several inhibitors for VEGF and its receptors
are consistent with the notion that other angiogenic factors are Experimental procedures
playing critical and indispensable roles in tumor angiogenesis
RT-PCR and Northern blotting(Kerbel and Folkman, 2002). Our finding of the Slit2 expression
Primary HUVECs were cultured as previously described (Geng et al., 1990).on cancerous tissues (Figure 5B) suggests that Slit2 is a novel
RT-PCR was performed as before (Ma and Geng, 2000). Primers used wereplayer in tumorigenesis.
human SLIT2 sense (3611) 5-GGT GAC GGA TCC CAT ATC GCG GTA
It should be pointed out that we have screened and found GAA CTC-3 and antisense (	4574) 5-GGA CAC CTC GAG CGT ACA GCC
the increased Slit2 expression in a number of tumor cell lines GCA CTT CAC-3; human ROBO1 sense (4440) 5-CCT ACA CAG ATG
ATC TTC C-3 and antisense (	4956) 5-CAG AGG AGC CTG CAG CTCand primary tumors in this study. However, there are two other
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AGC TTT CAG TTT CCT C-3; human -ACTIN sense (1) 5-ATG GAT GAT Tube formation assay
96-well cell culture plates were coated with 100 l/well of Matrigel andGAT ATC GCC GC-3 and antisense (	1127) 5-CTA GAA GCA TTT GCG
GTG G-3. Total RNAs from A375 cells and the primary culture of HUVECs incubated at 37
C for 30 min to promote gelling (Malinda et al., 1999).
HUVECs (passages 2 to 3) were resuspended at 1.3  105 cells per well inwere also probed with the 32P-labeled human Slit2 (1 kb), rat ROBO1 (2.1
kb), or human G3PDH (1.3 kb) cDNA fragments. M199 medium supplemented with 2% heat-inactivated fetal calf serum.
Aliquots of cells (0.1 ml per aliquot) were added to each Matrigel-containing
well. The tubular structures were identified and photographed at 12 to 18Cell lines
hr. The inhibition experiments of RoboN, R5, or chemical inhibitors wereStable human embryonic kidney 293 cell lines expressing full-length human
carried out as above.Slit2 with a c-myc tag at its carboxyl terminus (Slit2/293 cells), the extracellu-
lar portion of rat Robo1 (RoboN/293 cells) and full-length of rat Robo1
Xenografted tumor growth model(Robo1/293 cells) with a HA tag at their carboxyl termini, and the plain vector
A375 cells were transfected with the RoboN plasmid (RoboN/A375 cells),(V/293 cells) were established as previously described (Li et al., 1999; Wu
the Slit2 plasmid (Slit2/A375 cells), or the plain vector (V/375 cells) usinget al., 1999, 2001).
Lipofectin (Gibco) and selected by 400 g/ml hygromycin B (Sigma). The
stable single cell clones of RoboN/A375_C1, C2, and C3 cells, Slit2/A375_C1Antibody generation, immunoblotting, and immunostaining
and C2 cells as well as V/A375 cells were verified by immunoblotting withGST and His-tag fusion proteins of Slit2 (encoding 57–207 or 1272–1593
antibodies against Robo1, Slit2, VEGF, and -tubulin (as the loading control).amino acids of human Slit2) and Robo1 (encoding 1–168 or 961–1217 amino
They were resuspended at 5  106 cells/ml and an aliquot of 0.2 ml cellacids of rat Robo1) were constructed into pGEX-4T-1 (Amersham Pharmacia
suspension was injected subcutaneously into athymic nude mice (O’ReillyBiotech) and pET-30a() (Novagen) vectors and expressed according to the
et al., 1997). For antibody inhibition experiments, mice bearing A375 cellmanufacturers’ protocols. The purified GST fusion proteins were used as
tumors were treated with intraperitoneal injections of R5 or an IgG2b controlthe antigens to immunize rabbits and mice for generation of anti-Slit2 and
twice per week (1 mg per injection). Tumor volumes were determined byanti-Robo1 polyclonal and monoclonal antibodies. The purified His-tag fu-
external measurements and calculated according to the equation, V  [L sion proteins were used for affinity isolation of the polyclonal antibodies
W2]  0.52 (V  volume, L  length, and W  width). Mice were sacrificedand for ELISA assay during the screening of monoclonal antibodies. Equal
28–35 days later. Mouse blood was collected before sacrifice for leukocyteamounts of cell lysates (routinely verified by -tubulin immunoblotting;
counts, and myeloperoxidase activity for quantification of neutrophils withinSigma) were used for immunoblotting. For experiments of TNF- or heparin
the tumors was performed (Wang et al., 2002).treatment, A375 cells were cultured in the presence of either 300 units/
ml TNF-, 50 g/ml heparin, or both for 12 hr. Antibodies against CD31
Cell proliferation assay(PharMingen; a 1:50 dilution for cryostat sections), vWF (Antibody Diagnos-
All transfectants were grown in exponential phase and detached by trypsintica Inc.; a 1:200 dilution for paraffin-embedding and cryostat sections), Slit2
treatment. Viable cells (5  104 cells/ml) were plated into 96-well tissue(5 g/ml for paraffin-embedding sections), and Robo1 (20 g/ml for cryostat
culture plates (100 l complete medium/well) and cultured at 37
C in 5%sections) were used for immunohistochemical staining, as described before
CO2 atmosphere. At different time points, tetrazolium salt was added (20(Liu et al., 2001).
l/well) and incubated at 37
C for 4 hr. The insoluble blue formazan product
was solubilized by addition of 100 l/well 10% SDS/5% isobutanol. TheIsolation of Slit2 and RoboN
plates were read on a microtiter plate reader using a test wavelength of 570Recombinant Slit2 and RoboN proteins were purified from the conditioned
nm and a reference wavelength of 630 nm.medium by affinity chromatography using a 9E10 mAb to the c-myc tag (1
mg/ml Affi-Gel 10; Bio-Rad) or a HA11 mAb to HA, HA11 (BAbCO). Purified
Measurements of PI-3K activitySlit2 was silver stained and immunoblotted as before (Geng et al., 1997).
PI-3K activity assay was carried out as described before (Wallasch et al.,
1995). HUVECs were starved in a M199 medium containing 2% FCS for 2Boyden chamber assay
hr and then stimulated with 10 ng/ml Slit2 at 22
C for 15 min.The cell migration assay (Gho et al., 1999) was conducted in a 48-well micro-
chemotaxis chamber (Neuro Probe, Inc.). PVP-free polycarbonate mem-
Acknowledgmentsbranes (8 m pores) were coated with 1% gelatin. The bottom chambers
were loaded with or without Slit2 or bFGF (Sigma), while the upper chambers
We thank Li-Ping Liu, Hai-Bo Wang, Hai-Xiong Han, Xiao-Feng Niu, Qin Cai,were seeded with HUVECs (5  105 cells/ml), Robo1/293 cells (1  105
and Ji-Guo Liu for technical assistance. We are grateful to Dr. Gang Pei forcells/ml), or V/293 cells (5  105 cells/ml) resuspended in M199 medium or
teaching us Boyden chamber assay and for many constructive commentsDMEM supplemented with 1% heat inactivated fetal calf serum (FCS). For
during this study. This study was supported by grants from Chinese Academythe RoboN inhibition experiments, Slit2 was mixed with 5-fold RoboN in a
of Sciences (KSCX2-2-02), National Science Foundation of China (39925015,molar ratio at 4
C before adding to the bottom chambers. For antibody or
30130090, and 30270649), Special Funds for Major State Basic Researchchemical inhibition experiments, HUVECs were pretreated with the indicated
of China (G1999053907), and 973 Program (2002CB513000) from Chineseamounts of mouse IgG2b, R5, or chemical inhibitors at 37
C for 30 min, prior
Ministry of Science and Technology.to adding to the upper chambers. They were incubated at 37
C for 4 hr.
The filters were then fixed, stained with 0.5% crystal violet, and the cells
that had migrated through the filters were counted.
Received: March 24, 2003Directional migration assay
Revised: June 2, 2003The microscopic gradients of proteins were produced as described (Ho¨pker
Published: July 21, 2003et al., 1999). Briefly, a repetitive pressure injection of picoliter volumes of
0.15 M Slit2 or 1 M bFGF was applied through a micropipette with a tip
Referencesat the opening of 1 m. The 24-well culture plate was coated with a thin
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